Lead Product(s) : Farudodstat
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata
Details : ASLAN003 (farudodstat) is a potent oral DHODH inhibitor that suppresses immune cell proliferation and IFNγ secretion by blocking de novo production of pyrimidines required for DNA replication. It is being developed for alopecia areata.
Brand Name : ASLAN003
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 18, 2023
Lead Product(s) : Farudodstat
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Farudodstat
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ASLAN003 (farudodstat) is a potent oral DHODH inhibitor that suppresses immune cell proliferation and IFNγ secretion by blocking de novo production of pyrimidines required for DNA replication. It is being developed for alopecia areata.
Brand Name : ASLAN003
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 28, 2023
Lead Product(s) : Farudodstat
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Farudodstat
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : K2 HealthVentures
Deal Size : Undisclosed
Deal Type : Financing
ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures
Details : The company intends to use the proceeds of the loan facility to advance the clinical development of ASLAN003, a promising candidate for the potential treatment of autoimmune gastrointestinal and skin diseases, especially inflammatory bowel disease as wel...
Brand Name : ASLAN003
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 13, 2021
Lead Product(s) : Farudodstat
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : K2 HealthVentures
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Farudodstat
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : New research shows ASLAN003 to have the lowest potential for hepatotoxicity of the compounds tested despite being one of the most potent DHODH inhibitors.
Brand Name : ASLAN003
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 26, 2021
Lead Product(s) : Farudodstat
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Farudodstat
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ASLAN003 is a highly selective and potent inhibitor of human DHODH (IC50 = 35 nM) and has been shown to be more than 30 times more potent at inhibiting the DHODH enzyme in cell free and cell-based assays than the first generation inhibitor teriflunomide.
Brand Name : ASLAN003
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 16, 2020
Lead Product(s) : Farudodstat
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?